Founded roughly a decade ago, Bloomlife offers a wearable patch embedded with sensors that continuously monitors pregnant women to detect conditions such as hypertension and gestational diabetes without hospital visits. After the pandemic, the company pivoted from direct-to-consumer sales to a B2B model, selling through obstetricians and hospitals. Its technology is now prescribed by more than 120 doctors, a number set to grow more than ten-fold through a newly signed agreement with an employer group representing 2,700 gynecologists across 22 U.S. states. To support this expansion, Bloomlife plans to scale its commercial team from about twenty employees to thirty by year-end. The firm believes 120-150 active prescribers are sufficient for breakeven and had previously targeted profitability by mid-next year, but it has delayed that milestone to focus on onboarding the new partners. Bloomlife remains focused on the U.S. market for the next two years, with Europe and Asia as longer-term opportunities. Cumulatively, the company has raised $34 million to date.

Total raised

$12M

Funding rounds

2

Latest round

Equity

Latest activity

Sep 2025